AD80是一种多激酶抑制剂，在多种肝细胞癌临床前动物模型中具有抗肿瘤活性，AD80在血浆中的含量通过美迪西进行LC-MS/MS测定

Liver cancer is the fourth greatest cause of cancer related mortality. AD80 is a multi-kinase inhibitor with anti-tumoral activity across a variety of hepatocellular carcinoma (HCC) preclinical models, including mouse xenografts. AD80 is highly active in a tumor xenograft model. Experimental dosing for AD80 was determined from maximum tolerated dosage (MTD) studies and pharmacokinetic (PK) analysis. Quantities of AD80 in blood plasma were determined by LC-MS/MS at Medicilon. 

Reference:

Jia Xin Yu, et al. Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology. Mol Cancer Ther. 2019 Sep;18(9):1506-1519. doi: 10.1158/1535-7163.MCT-18-0571.